CSL Vifor and Travere Therapeutics announced that the European Medicines Agency’s, or EMA, CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion greater than1.0 g/day. IgAN is a rare kidney disorder and a leading cause of kidney failure. The CHMP opinion provides the basis for the European Commission’s final decision regarding CMA for sparsentan. If approved in Europe, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for the treatment of IgAN.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- New Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?
- Travere Therapeutics price target raised to $14 from $10 at Citi
- Travere Therapeutics reports Q4 EPS (94c), consensus ($1.22)
- Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- TVTX Upcoming Earnings Report: What to Expect?
